Anupam Rasayan India Limited — Investor Meet, 25-10-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Anupam Rasayan reported stellar Q2 FY26 results with consolidated revenue of ₹731.4 crore (+148.8% YoY) and PAT of ₹57.15 crore (+86.6% YoY). H1 FY26 revenue of ₹1,217.2 crore already surpassed FY25’s total. Strong growth was driven by Life Science Specialty (Pharma up 201% YoY) and Performance Materials (up 306% YoY). Q2 EBITDA margins were ~19.5%, with a ~25% outlook for upcoming quarters. The order book stands healthy at ₹14,646 crore. Working capital days significantly improved (409 to 247), and net debt reduced to ₹730 crore. Management is optimistic about continued growth, especially in polymers, and open to M&A opportunities.